Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Assemblies of JAG1 and JAG2 determine tracheobronchial cell fate in mucosecretory lung disease
Susan D. Reynolds, … , Tendy Chiang, Estelle Cormet-Boyaka
Susan D. Reynolds, … , Tendy Chiang, Estelle Cormet-Boyaka
Published July 12, 2022
Citation Information: JCI Insight. 2022;7(15):e157380. https://doi.org/10.1172/jci.insight.157380.
View: Text | PDF
Research Article Cell biology Stem cells

Assemblies of JAG1 and JAG2 determine tracheobronchial cell fate in mucosecretory lung disease

  • Text
  • PDF
Abstract

Mucosecretory lung disease compromises airway epithelial function and is characterized by goblet cell hyperplasia and ciliated cell hypoplasia. Goblet and ciliated cell types are derived from tracheobronchial stem/progenitor cells via a Notch-dependent mechanism. Although specific arrays of Notch receptors regulate cell fate determination, the function of the ligands Jagged1 (JAG1) and JAG2 is unclear. This study examined JAG1 and JAG2 function using human air-liquid-interface cultures that were treated with γ-secretase complex (GSC) inhibitors, neutralizing peptides/antibodies, or WNT/β-catenin pathway antagonists/agonists. These experiments revealed that JAG1 and JAG2 regulated cell fate determination in the tracheobronchial epithelium; however, their roles did not adhere to simple necessity and sufficiency rules. Biochemical studies indicated that JAG1 and JAG2 underwent posttranslational modifications that resulted in generation of a JAG1 C-terminal peptide and regulated the abundance of full-length JAG2 on the cell surface. GSC and glycogen synthase kinase 3 were implicated in these posttranslational events, but WNT agonist/antagonist studies and RNA-Seq indicated a WNT-independent mechanism. Collectively, these data suggest that posttranslational modifications create distinct assemblies of JAG1 and JAG2, which regulate Notch signal strength and determine the fate of tracheobronchial stem/progenitor cells.

Authors

Susan D. Reynolds, Cynthia L. Hill, Alfahdah Alsudayri, Scott W. Lallier, Saranga Wijeratne, Zheng Hong Tan, Tendy Chiang, Estelle Cormet-Boyaka

×

Figure 4

JAG2 subcellular location.

Options: View larger image (or click on image) Download as PowerPoint
JAG2 subcellular location.
Human bronchial basal cells were differentiat...
Human bronchial basal cells were differentiated in ALI using H&H medium. (A–C) Immunofluorescence was used to detect JAG2 (red) and CTNNB1 (green) on proliferation (A) day 5, (B) day 4, or (C) day 8. Nuclei were detected with DAPI (blue). Each montage presents single-color and merged images. White arrows, cortical JAG2; yellow arrows, JAG2-high cells; blue arrows, JAG2-positive cells; pink arrows, JAG2-negative cells. Original magnification, ×400. (D and E) Immunofluorescence analysis of (D) HES1 (red) and (E) RBPJ (red) on day 8. Nuclei were detected with DAPI (blue). Original magnification, ×200. (F) Western blot analysis of JAG2 on day 4 (lane 1) and day 8 (lane 2). The full-length band is labeled JAG2. Two samples were analyzed. (G) Coimmunoprecipitation analysis of full-length JAG2 and CTNNB1 on day 8. Proteins were immunoprecipitated with an N-terminus–specific (N-term–specific) CTNNB1 antibody. Precipitates were analyzed for CTNNB1 using a C-terminus–specific (C-term–specific) CTNNB1 antibody, N-term–specific CTNNB1 antibody, or a JAG2 N-term–specific antibody. Three samples were analyzed. (H) Analysis of Jag2 mRNA abundance on day 2, day 4, and day 8. (I) Western blot analysis of full-length JAG2 protein abundance on day 2, day 4, and day 8. (J and K) Western blot analysis of full-length JAG2 abundance in cultures that were (J) treated with DMSO, 25 μM DAPT, or 10 μM LY on day 4 and day 6 and harvested on day 8 or (K) treated on day 8 and day 10 and harvested on day 12. All quantitative data are presented as the mean ± SD, n = 3. Normally distributed data were analyzed by t test. Nonnormally distributed data were analyzed by Mann-Whitney test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts